Skip to main content

Preop Stereotactic Radiosurgery May Aid Outcomes With Resected Brain Metastases

Medically reviewed by Drugs.com.

By Lori Solomon HealthDay Reporter

MONDAY, July 10, 2023 -- Preoperative stereotactic radiosurgery (SRS) may be effective for patients with resected brain metastases, according to a study published online June 8 in JAMA Oncology.

Roshan S. Prabhu, M.D., from Atrium Health in Charlotte, North Carolina, and colleagues assessed outcomes and prognostic factors after preoperative SRS for patients with resected brain metastases. The analysis included 404 patients with resected brain metastases from solid cancers with a median dose to 15 Gy in one fraction or 24 Gy in three fractions delivered at a median of two days before resection.

The researchers found that the two-year cavity local recurrence rate was 13.7 percent. Cavity local recurrence risk was associated with systemic disease status, extent of resection, SRS fractionation, type of surgery (piecemeal versus en bloc), and primary tumor type. The two-year meningeal disease rate was 5.8 percent, with risk associated with the extent of resection, primary tumor type, and posterior fossa location. For adverse radiation effects, the two-year rate for any grade was 7.4 percent. Median overall survival was 17.2 months, which was most strongly predicted by systemic disease status, extent of resection, and primary tumor type.

"In this cohort study, the rates of cavity local recurrence, adverse radiation effects, and meningeal disease after preoperative SRS were found to be notably low," the authors write.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted July 2023

Read this next

Second Tumors Are Rare After Chimeric Antigen Receptor T-Cell Therapy

FRIDAY, June 14, 2024 -- Second tumors are rarely seen after chimeric antigen receptor (CAR) T-cell therapy, according to a study published in the June 13 issue of the New England...

Health Care Spending Growth Projected to Outpace GDP to 2032

THURSDAY, June 13, 2024 -- Health care spending growth is projected to outpace that of the gross domestic product (GDP) during the coming decade, according to a study published...

Generation X Experiencing Larger Per-Capita Increases in Cancer Incidence

WEDNESDAY, June 12, 2024 -- Generation X is experiencing larger per-capita increases in the incidence of cancers than Baby Boomers, according to a study published online June 10...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.